AR071910A1 - Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. - Google Patents
Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.Info
- Publication number
- AR071910A1 AR071910A1 ARP090101881A ARP090101881A AR071910A1 AR 071910 A1 AR071910 A1 AR 071910A1 AR P090101881 A ARP090101881 A AR P090101881A AR P090101881 A ARP090101881 A AR P090101881A AR 071910 A1 AR071910 A1 AR 071910A1
- Authority
- AR
- Argentina
- Prior art keywords
- hpv
- vaccine
- measles
- recombinant
- hpv6
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 9
- 239000013598 vector Substances 0.000 title abstract 4
- 241000701806 Human papillomavirus Species 0.000 abstract 10
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 241000712079 Measles morbillivirus Species 0.000 abstract 5
- 201000005505 Measles Diseases 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 201000006082 Chickenpox Diseases 0.000 abstract 1
- 101150071673 E6 gene Proteins 0.000 abstract 1
- 101150013359 E7 gene Proteins 0.000 abstract 1
- 241000701828 Human papillomavirus type 11 Species 0.000 abstract 1
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 1
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 abstract 1
- 101100049401 Human papillomavirus type 16 L2 gene Proteins 0.000 abstract 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 abstract 1
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 abstract 1
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 abstract 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 abstract 1
- 208000005647 Mumps Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 206010046980 Varicella Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940031567 attenuated vaccine Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229940041323 measles vaccine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010805 mumps infectious disease Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 201000005404 rubella Diseases 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Vacunas combinadas contra el sarampion y el virus del papiloma humano (HPV). Vectores del virus de sarampion recombinantes que contienen cido nucleico heterologo que codifica uno o varios ant¡genos derivados del HPV, preferentemente, el ant¡geno L1 de la c pside mayor, el ant¡geno L2 de la c pside menor, oncoprote¡nas del gen temprano E6 y gen temprano E7 del HPV tipo 16, y opcionalmente de los tipos 18, 6 y 11. En una primera realizacion, las vacunas profil cticas se generan expresando ant¡genos HPV, preferentemente L1 y/o L2. En otra realizacion, las vacunas terapeuticas se generan expresando prote¡nas E6 y E7, y opcionalmente L1 y L2. Reivindicacion 1: Una vacuna para el sarampion y el HPV combinada caracterizada porque comprende los virus de la vacuna para el sarampion recombinados que expresan ant¡genos HPV capaces de sacar una respuesta inmunologica y proporcionar proteccion contra el sarampion y el HPV, Reivindicacion 11: Un vector caracterizado porque comprende la secuencia de nucleotidos de ant¡genos de diferentes tipos de HPV y sarampion. Reivindicacion 14: El vector tal como se reivindica en la reivindicacion 11, caracterizado porque el ant¡geno se selecciona de prote¡nas L1 o L2 o E6 o E7 de HPV-16, HPV-18, HPV-6 y HPV-11. Reivindicacion 23: La vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes caracterizada porque comprende el virus del sarampion recombinante que tiene insertada una secuencia de cido nucleico que codifica el HPV16-L1 o HPV18-L1 o HPV6-L1 o HPV11-L1 o HPV16-L2 o HPV18-L2 o HPV6-L2 o HPV11-L2 o HPV1I6-E6 o HPV18-E6 o HPV6-E6 o HPV16-E7 o HPV18-E7 o HPV6-E7 o cualquiera de sus combinaciones. Reivindicacion 27: Una vacuna tal corno se reivindica en la reivindicacion 25, caracterizada porque el adyuvante es una interleuquina, preferentemente interleuquina 2. Reivindicacion 28 :Una vacuna tal como se reivindica en cualquiera de las reivindicaciones precedentes, caracterizada porque la vacuna consiste esencialmente de al menos uno de los virus del HPV y el sarampion recombinantes o una mezcla de dos o varios de tales virus. Reivindicacion 34: Una vacuna tal corno se reivindica en las reivindicaciones precedentes es un componente de una vacuna combinada caracterizada porque los otros componentes son virus de rubeola, paperas, varicela u otro virus de vacuna atenuada viva, atenuada naturalmente o recombinante, solos o combinados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1113MU2008 | 2008-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071910A1 true AR071910A1 (es) | 2010-07-21 |
Family
ID=42316922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101881A AR071910A1 (es) | 2008-05-26 | 2009-05-26 | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9623098B2 (es) |
| EP (1) | EP2280728B1 (es) |
| JP (1) | JP5726727B2 (es) |
| CN (2) | CN106377767A (es) |
| AR (1) | AR071910A1 (es) |
| AU (1) | AU2009336562B2 (es) |
| BR (1) | BRPI0909547A2 (es) |
| CA (1) | CA2722847C (es) |
| EA (1) | EA027784B1 (es) |
| ES (1) | ES2565846T3 (es) |
| TW (1) | TWI561244B (es) |
| WO (1) | WO2010079505A2 (es) |
| ZA (1) | ZA201007595B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1268985A1 (en) | 2000-03-31 | 2003-01-02 | NORTHERN RESEARCH & ENGINEERING CORPORATION | Solid-fueled power generation system with carbon dioxide sequestration and method therefor |
| DK1375670T3 (da) * | 2002-06-20 | 2013-09-23 | Pasteur Institut | Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger |
| PT1375512E (pt) | 2002-06-20 | 2009-09-23 | Pasteur Institut | Adnc infeccioso de uma estirpe de vacina aprovada do vírus do sarampo. utilização de composições imunogénicas |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| CN102458427B (zh) * | 2009-05-05 | 2016-02-03 | 卡迪拉保健有限公司 | 麻疹-疟疾联合疫苗 |
| CN107723299B (zh) * | 2011-10-12 | 2022-02-01 | 宾夕法尼亚大学理事会 | 用于人乳头状瘤病毒的疫苗及其使用方法 |
| EP2780034A1 (en) * | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
| HK1220905A1 (zh) | 2013-03-12 | 2017-05-19 | The Trustees Of The University Of Pennsylvania | 用於人乳头状瘤病毒的改进疫苗及其使用方法 |
| CN105801704B (zh) * | 2014-12-31 | 2020-06-02 | 艾托金生物医药（苏州）有限公司 | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 |
| CN104830869B (zh) * | 2015-04-30 | 2018-06-01 | 武汉凯德维斯生物技术有限公司 | 与宫颈癌发生相关的hpv整合的基因位点及其应用 |
| JP7048482B2 (ja) | 2015-08-03 | 2022-04-05 | アメリカ合衆国 | Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用 |
| RU2681174C1 (ru) * | 2018-07-12 | 2019-03-04 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина |
| BR102019025802A2 (pt) * | 2019-12-05 | 2022-01-18 | Instituto Butantan | Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113809D0 (en) | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
| DK1359156T3 (da) | 1991-07-19 | 2007-04-10 | Univ Queensland | Vaccine mod humanpapillomavirus |
| WO1994000152A1 (en) | 1992-06-25 | 1994-01-06 | Georgetown University | Papillomavirus vaccines |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| EP0688227B1 (en) | 1993-03-09 | 2005-05-25 | The University Of Rochester | Production of human papillomavirus capsid protein and virus-like particles |
| DK0780475T4 (da) | 1995-08-09 | 2006-10-23 | Schweiz Serum & Impfinst | Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus |
| NZ506602A (en) * | 1998-03-09 | 2003-02-28 | Smithkline Beecham Biolog S | Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii |
| SI1126876T1 (sl) * | 1998-10-16 | 2007-08-31 | Glaxosmithkline Biolog Sa | Adjuvantni sistemi in vakcine |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| DK1375670T3 (da) * | 2002-06-20 | 2013-09-23 | Pasteur Institut | Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger |
| AU2003295502A1 (en) | 2002-11-12 | 2004-06-03 | Yucheng Chang | Adenoviral vector vaccine |
| CA2432738A1 (en) * | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| EP1877548B1 (en) * | 2005-01-12 | 2016-01-06 | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services | Attenuated human parainfluenza virus, methods and uses thereof |
-
2009
- 2009-05-26 ES ES09828417.7T patent/ES2565846T3/es active Active
- 2009-05-26 AR ARP090101881A patent/AR071910A1/es unknown
- 2009-05-26 CN CN201610737988.9A patent/CN106377767A/zh active Pending
- 2009-05-26 AU AU2009336562A patent/AU2009336562B2/en not_active Ceased
- 2009-05-26 EA EA201071366A patent/EA027784B1/ru not_active IP Right Cessation
- 2009-05-26 CA CA2722847A patent/CA2722847C/en not_active Expired - Fee Related
- 2009-05-26 CN CN2009801194069A patent/CN102099053A/zh active Pending
- 2009-05-26 WO PCT/IN2009/000302 patent/WO2010079505A2/en not_active Ceased
- 2009-05-26 TW TW098117618A patent/TWI561244B/zh not_active IP Right Cessation
- 2009-05-26 BR BRPI0909547-0A patent/BRPI0909547A2/pt not_active Application Discontinuation
- 2009-05-26 US US12/993,693 patent/US9623098B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2011511167A patent/JP5726727B2/ja active Active
- 2009-05-26 EP EP09828417.7A patent/EP2280728B1/en active Active
-
2010
- 2010-10-25 ZA ZA2010/07595A patent/ZA201007595B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010079505A2 (en) | 2010-07-15 |
| TW201010718A (en) | 2010-03-16 |
| TWI561244B (en) | 2016-12-11 |
| EP2280728A2 (en) | 2011-02-09 |
| EA201071366A1 (ru) | 2011-06-30 |
| AU2009336562B2 (en) | 2012-12-20 |
| EP2280728B1 (en) | 2016-03-02 |
| WO2010079505A3 (en) | 2010-11-04 |
| US20110129493A1 (en) | 2011-06-02 |
| US9623098B2 (en) | 2017-04-18 |
| BRPI0909547A2 (pt) | 2019-03-06 |
| JP5726727B2 (ja) | 2015-06-03 |
| EA027784B1 (ru) | 2017-09-29 |
| ZA201007595B (en) | 2011-09-28 |
| CA2722847A1 (en) | 2010-07-15 |
| CN106377767A (zh) | 2017-02-08 |
| JP2011524863A (ja) | 2011-09-08 |
| CN102099053A (zh) | 2011-06-15 |
| CA2722847C (en) | 2019-12-17 |
| AU2009336562A1 (en) | 2010-07-15 |
| ES2565846T3 (es) | 2016-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071910A1 (es) | Vacuna combinada para el papiloma humano y el sarampion. vector. huesped. | |
| CY1124618T1 (el) | Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
| EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| MX344069B (es) | Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral. | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| MY170659A (en) | Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| MX2014007516A (es) | Procesos que utilizan vlps con capsides resistentes a hidrolasas. | |
| EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
| EA201691120A1 (ru) | Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса | |
| PH12013501116A1 (en) | Raccoon poxvirus expressing rabies glycoproteins | |
| MX390966B (es) | Vacunas contra el dengue | |
| AR101840A1 (es) | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene | |
| CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
| CO6670515A2 (es) | Vectores de parapoxvirus | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
| MX2013000787A (es) | Vectores de parapoxvirus. | |
| AR109540A1 (es) | Moléculas promotoras para expresar antígenos virales | |
| EA202092164A1 (ru) | Новый ehv с инактивированным ul18 и/или ul8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |